Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05378529 · ClinicalTrials.gov registry record · NA
A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)
A NA study of Atherosclerotic Cardiovascular Disease, sponsored by Amgen.
- Completed
- Registry status
- NA
- Development phase
- 39,480
- Enrollment target
- 20
- Study locations
NCT05378529: Completed NA study of Atherosclerotic Cardiovascular Disease, sponsored by Amgen.
NCT05378529 is a NA study of Atherosclerotic Cardiovascular Disease that has completed, run by Amgen. The registered enrollment target is 39,480 participants, above the 5,688-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (594% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05378529, a NA study of Atherosclerotic Cardiovascular Disease, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- NA
- Development phase
- 39,480 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: * Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD * Evaluate the distribution of Lp(a) value in participants with documented history of ASCVD by demographics and regions
Conditions Studied
Interventions
- OTHER Lp(a) Screening
Study Locations (20)
California
- Care Access - Berkeley - Berkeley
- National Heart Institute - Beverly Hills
- NorCal Medical Research, Inc - Greenbrae
- America Clinical Trials - Tarzana
- Med Partners, Inc dba Premiere Medical Center, Inc - Toluca Lake
Florida
- Excel Medical Clinical Trials - Boca Raton
- Bay Area Cardiology - Brandon
- Clearwater Cardiovascular Consultants - Clearwater
- Cardiology Associates Research LLC - Daytona Beach
- The Cardiac and Vascular Institute Research - Gainesville
Alabama
- Ascension Saint Vincents Birmingham - Birmingham
- Grandview Medical Center Affinity Cardiovascular Specialists, LLC - Birmingham
- Heart Center Research LLC - Huntsville
- Mobile Heart Specialists PC - Mobile
Arizona
- Care Access - Mesa - Mesa
- Elite Clinical Studies LLC - Phoenix
Alaska
- Alaska Cardiovascular Research Foundation - Anchorage
Arkansas
- Arkansas Cardiology - Little Rock
Colorado
- UCHealth Memorial Central - Colorado Springs
Connecticut
- Cardiology Associates of Fairfield County PC - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39,480 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2023-12-30 |
| Phase | NA |
What the finished NCT05378529 record still lists
NCT05378529 is an interventional study that assigns participants to a tested intervention. Its 39,480 participants enrollment target places it among the larger protocols in the corpus, above the 5,688-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (594% higher).
The record links to 1 condition, with Atherosclerotic Cardiovascular Disease appearing as the primary indexed condition, and to 1 intervention - of which Lp(a) Screening is the first listed.
NCT05378529 names 20 study sites across 8 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT05378529 about?
NCT05378529 is a clinical study titled "A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)". The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: * Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD * Eval...
What is the current status of trial NCT05378529?
This trial is currently completed. It is a NA study. The enrollment target is 39,480 participants. The study started on 2022-04-19. Estimated completion is 2023-12-30.
What conditions does trial NCT05378529 study?
This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease.
What interventions are being tested in trial NCT05378529?
The interventions under investigation include: Lp(a) Screening (OTHER).
Who is sponsoring clinical trial NCT05378529?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05378529 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerotic Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05378529's enrollment target sits among peer trials
39,480 2nd of 21 the highest of 21 other Atherosclerotic Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerotic Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients
RECRUITING · NA
-
Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure
RECRUITING · NA
-
The Young Heart Study
ACTIVE NOT RECRUITING · NA
-
Behavioral Economic Approaches to Increase Physical Activity Among Patients With Elevated Risk for Cardiovascular Disease
COMPLETED · NA
-
Recipe for Heart Health
COMPLETED · NA
-
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
- NCT04994756 · 40,000 participants
Stroke Thrombectomy and Aneurysm Registry
- NCT06768814 · 40,000 participants · NA
Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data
- NCT07109427 · 40,000 participants · NA
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI